Abcellera Biologics Inc
NASDAQ:ABCL
| US |
|
Fubotv Inc
NYSE:FUBO
|
Media
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
C
|
C3.ai Inc
NYSE:AI
|
Technology
|
| US |
|
Uber Technologies Inc
NYSE:UBER
|
Road & Rail
|
| CN |
|
NIO Inc
NYSE:NIO
|
Automobiles
|
| US |
|
Fluor Corp
NYSE:FLR
|
Construction
|
| US |
|
Jacobs Engineering Group Inc
NYSE:J
|
Professional Services
|
| US |
|
TopBuild Corp
NYSE:BLD
|
Consumer products
|
| US |
|
Abbott Laboratories
NYSE:ABT
|
Health Care
|
| US |
|
Chevron Corp
NYSE:CVX
|
Energy
|
| US |
|
Occidental Petroleum Corp
NYSE:OXY
|
Energy
|
| US |
|
Matrix Service Co
NASDAQ:MTRX
|
Construction
|
| US |
|
Automatic Data Processing Inc
NASDAQ:ADP
|
Technology
|
| US |
|
Qualcomm Inc
NASDAQ:QCOM
|
Semiconductors
|
| US |
|
Ambarella Inc
NASDAQ:AMBA
|
Semiconductors
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
2.39
5.97
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
|
|
Fubotv Inc
NYSE:FUBO
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
C
|
C3.ai Inc
NYSE:AI
|
US |
|
|
Uber Technologies Inc
NYSE:UBER
|
US |
|
|
NIO Inc
NYSE:NIO
|
CN |
|
|
Fluor Corp
NYSE:FLR
|
US |
|
|
Jacobs Engineering Group Inc
NYSE:J
|
US |
|
|
TopBuild Corp
NYSE:BLD
|
US |
|
|
Abbott Laboratories
NYSE:ABT
|
US |
|
|
Chevron Corp
NYSE:CVX
|
US |
|
|
Occidental Petroleum Corp
NYSE:OXY
|
US |
|
|
Matrix Service Co
NASDAQ:MTRX
|
US |
|
|
Automatic Data Processing Inc
NASDAQ:ADP
|
US |
|
|
Qualcomm Inc
NASDAQ:QCOM
|
US |
|
|
Ambarella Inc
NASDAQ:AMBA
|
US |
This alert will be permanently deleted.
Abcellera Biologics Inc
Wall Street
Price Targets
ABCL Price Targets Summary
Abcellera Biologics Inc
According to Wall Street analysts, the average 1-year price target for
ABCL
is 12.53 USD
with a low forecast of 5.05 USD and a high forecast of 29.4 USD.
ABCL Last Price Targets
Abcellera Biologics Inc
The latest public price target was made on Nov 5, 2024 by
Gary Nachman
from
BMO Capital
,
who expects
ABCL
stock to
rise by 81%
over the next 12 months.
You can read more about this price target by viewing
the article on StreetInsider.
| Analyst | Price Target | Date | Article |
|---|---|---|---|
Gary Nachman
BMO Capital
|
5
USD
Upside 81% |
2 weeks ago
Nov 5, 2024
|
AbCellera Biologics (ABCL) PT Lowered to $5 at BMO Capital
StreetInsider
|
Scott Schoenhaus
KeyBanc
|
5
USD
Upside 81% |
3 months ago
Aug 23, 2024
|
KeyBanc Reiterates Overweight Rating on AbCellera Biologics (ABCL)
StreetInsider
|
|
Scott Schoenhaus
KeyBanc
|
7
USD
Upside 154% |
6 months ago
May 8, 2024
|
AbCellera Biologics (ABCL) PT Lowered to $7 at KeyBanc
StreetInsider
|
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.
What is ABCL's stock price target?
Price Target
12.53
USD
According to Wall Street analysts, the average 1-year price target for
ABCL
is 12.53 USD
with a low forecast of 5.05 USD and a high forecast of 29.4 USD.
What is Abcellera Biologics Inc's Revenue forecast?
Projected CAGR
26%
For the last 4 years the
compound annual growth rate for
Abcellera Biologics Inc's revenue is
35%.
The projected
CAGR
for the next 3 years is
26%.
You don't have any saved screeners yet
